Editas Medicine
-
Gene-editing firms sign on to statement of ethical principles, with emphasis on germline editing
The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
-
Editas, Allergan open first trial of in vivo CRISPR therapy
One of the four sites of the trial, in a rare form of inherited blindness, is currently listed as open for enrollment, and the companies plan to dose the first patient soon.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
Editas Medicine CEO steps down as company moves into product development stage
Shares of gene-editing companies were down Tuesday morning following the news, but analysts sought to reassure investors about Editas.
-
Federal appeals court rules for Broad Institute in CRISPR patent case
The decision in favor of Broad Institute of MIT and Harvard by a panel of judges at the US Court of Appeals for the Federal Circuit leaves UC Berkeley with few options to appeal further.
-
CRISPR clinical trial hits regulatory speedbump
FDA slaps clinical hold on Crispr Therapeutics and Vertex Pharmaceuticals’ upcoming gene-editing trial.
-
Gene editing remains early stage, but Big Pharma has taken notice
Gene editing offers near-limitless medical potential. The challenge is putting it into medical practice. So how is gene editing progressing, in terms of biotech pipelines, investment, and therapeutic approvals?
-
CRISPR player Editas Medicine sets terms for $122M IPO
The hot gene editing company plans to raise a comparatively small amount of money in its IPO, when considering the amount of money it’s raised privately.
-
CRISPR gene editing: A commercial timeline
CRISPR gene editing is heralded one of the most promising technologies today – and it’s ramping up fast. Here’s a commercial timeline – from just the past year.
-
These infographics outline Editas’ post-IPO strategy
Looks like the gene editing startup plans to start with simple gene editing techniques that focus heavily on diseases of the eye.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Editas to deploy CRISPR therapy in humans by 2017
Looks like CRISPR is headed to the clinic: Editas Medicine just announced that it’ll bring this gene editing technology to human trials by 2017.
-
NIH study shows why HIV drugs should be given earlier, Juno Therapeutics in $737M deal with Editas Medicine (Morning Read)
An NIH study has shown that giving HIV drugs when patients are initially diagnosed with the disease is more effective than waiting for the white blood cell counts to drop.